View Older Stories View More Recent Stories

May 3, 2021 06:45AM Merck Hosts Organon Investor Day Outlining New Company’s Vision, Focus and Business Model for Sustained Growth
Apr 29, 2021 06:30AM Merck Announces First-Quarter 2021 Financial Results
Apr 27, 2021 06:47AM Merck to Hold Investor Briefing Featuring Organon on May 3
Apr 27, 2021 06:45AM Amid Humanitarian Crisis in India, Merck Announces Voluntary Licensing Agreements with Five Indian Generics Manufacturers to Accelerate and Expand Global Access to Molnupiravir, an Investigational Ora
Apr 26, 2021 06:45AM Merck Accelerates Climate Goals; Announces Carbon Neutrality in Operations by 2025
Apr 15, 2021 06:49AM Merck (MRK), Ridgeback Biotherapeutics announce data from MOVe-IN indicate that molnupiravir is unlikely to demonstrate clinical benefit in hospitalized Covid-19 patients
Apr 15, 2021 06:46AM Merck (MRK) to Discontinue Development of MK-7110 for COVID-19
Apr 15, 2021 06:46AM Merck to Discontinue Development of MK-7110 for COVID-19
Apr 15, 2021 06:45AM Merck and Ridgeback Biotherapeutics Provide Update on Progress of Clinical Development Program for Molnupiravir, an Investigational Oral Therapeutic for the Treatment of Mild-to-Moderate COVID-19
Apr 14, 2021 08:00AM Merck Expands Safer Childbirth Cities Initiative to 20th Community-Led Project Advancing Maternal Health Equity During Black Maternal Health Week
Apr 8, 2021 06:46AM Merck's (MRK) KEYTRUDA Demonstrated Superior Disease-Free Survival Compared With Placebo as Adjuvant Therapy in Patients With RCC Following Surgery
Apr 8, 2021 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Superior Disease-Free Survival (DFS) Compared With Placebo as Adjuvant Therapy in Patients With Renal Cell Carcinoma (RCC) Following Surgery
Apr 7, 2021 07:10AM IMV Inc. (IMV) Announces Company-Sponsored Clinical Trial in Patients with r/rDLBCL in Collaboration with Merck (MRK) Following Feedback from FDA
Apr 1, 2021 08:35AM Merck (MRK) Completes Acquisition of Pandion Therapeutics (PAND)
Apr 1, 2021 08:30AM Merck Completes Acquisition of Pandion Therapeutics
Mar 30, 2021 07:34AM Merck (MRK) Announces Acquisition of Alydia Health on behalf of its Planned Spinoff of Organon
Mar 30, 2021 07:30AM Merck Announces Acquisition of Alydia Health on behalf of its Planned Spinoff of Organon
Mar 30, 2021 06:46AM Merck (MRK) Receives Positive EU CHMP Opinion for Updated Label of KEYTRUDA To Include Results of Phase 3 KEYNOTE-361 Trial in Certain Adult Patients with Locally Advanced or Metastatic Urothelial Can
Mar 30, 2021 06:45AM Merck Receives Positive EU CHMP Opinion for Updated Label of KEYTRUDA® (pembrolizumab) To Include Results of Phase 3 KEYNOTE-361 Trial in Certain Adult Patients with Locally Advanced or Metastatic Ur
Mar 29, 2021 04:16PM Merck (MRK) Receives CRL From US FDA for Supplemental Biologics License Application for KEYTRUDA in High-Risk Early-Stage TNBC
Mar 29, 2021 04:15PM Merck Receives Complete Response Letter From US FDA for Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
Mar 29, 2021 06:45AM Merck to Hold First-Quarter 2021 Sales and Earnings Conference Call on April 29
Mar 24, 2021 06:45AM Merck (MRK) Appoints Caroline Litchfield as CFO
Mar 24, 2021 06:45AM Merck Appoints Caroline Litchfield Chief Financial Officer
Mar 23, 2021 06:50AM FDA Approves Merck’s (MRK) KEYTRUDA Plus Platinum- and Fluoropyrimidine-Based Chemotherapy for Treatment of Certain Patients With Locally Advanced or Metastatic Esophageal or GEJ Carcinoma
Mar 23, 2021 06:45AM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Platinum- and Fluoropyrimidine-Based Chemotherapy for Treatment of Certain Patients With Locally Advanced or Metastatic Esophageal or Gastroesoph
Mar 19, 2021 06:46AM Merck (MRK) Announces KEYTRUDA Plus LENVIMA Significantly Improved PFS and OS Versus Chemotherapy in Patients With Advanced Endometrial Cancer
Mar 19, 2021 06:45AM KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Significantly Improved Progression-Free Survival and Overall Survival Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following
Mar 17, 2021 04:28PM Merck (MRK) Files Form 10 Related to Planned Spinoff of Organon & Co.
Mar 17, 2021 04:27PM Merck Announces Filing of Form 10 Registration Statement in Connection with Planned Spinoff of Organon & Co.
Mar 17, 2021 11:40AM MilliporeSigma Accelerates European Expansion Plans for Single-use Products Critical to Manufacturing Vaccines and Lifesaving Therapies
Mar 17, 2021 07:03AM EC Approves Expanded Indication for Merck’s (MRK) KEYTRUDA in Adult and Pediatric Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Mar 17, 2021 07:00AM European Commission Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) in Adult and Pediatric Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)
Mar 17, 2021 06:45AM Mike Nally to Leave Merck; Frank Clyburn to Lead All Merck Human Health
Mar 16, 2021 06:45AM Merck (MRK) Receives Priority Review From FDA for New Drug Application for HIF-2α Inhibitor Belzutifan
Mar 16, 2021 06:45AM Merck Receives Priority Review From FDA for New Drug Application for HIF-2α Inhibitor Belzutifan (MK-6482)
Mar 15, 2021 06:47AM Merck to Host Investor Briefing to Discuss Broad HIV Development Program and Newly Announced Collaboration with Gilead
Mar 15, 2021 06:46AM Gilead (GILD), Merck (MRK) Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV
Mar 15, 2021 06:45AM Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV
Mar 8, 2021 11:40AM Merck (MRK) Presents Results from Phase 1 Trial Evaluating Investigational Islatravir Subdermal Implant for the Prevention of HIV-1 Infection at CROI 2021
Mar 8, 2021 11:40AM Merck Presents Results from Phase 1 Trial Evaluating Investigational Islatravir Subdermal Implant for the Prevention of HIV-1 Infection at CROI 2021
Mar 6, 2021 12:01AM Ridgeback Biotherapeutics and Merck Announce Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir
Mar 4, 2021 06:48AM Merck (MRK) Begins Tender Offer to Acquire Pandion Therapeutics (PAND)
Mar 4, 2021 06:45AM Merck Begins Tender Offer to Acquire Pandion Therapeutics
Mar 3, 2021 06:45AM Merck to Present at the Barclays Global Healthcare Conference
Mar 3, 2021 06:45AM Merck to Present New Data from Various HIV Research and Development Programs at CROI 2021
Mar 2, 2021 04:32PM Merck (MRK) Confirms It Will Help Produce Johnson & Johnson’s (JNJ) COVID-19 Vaccine;
Mar 2, 2021 04:30PM Merck to Help Produce Johnson & Johnson’s COVID-19 Vaccine; BARDA to Provide Merck With Funding to Expand Merck’s Manufacturing Capacity for COVID-19 Vaccines and Medicines
Mar 2, 2021 08:00AM Merck Announces Fifth Round of Global Grants to Tackle Maternal Mortality and Promote Health Equity Worldwide
Mar 1, 2021 04:12PM Merck (MRK) Provides Update on KEYTRUDA Indication in Metastatic Small Cell Lung Cancer in the US
View More Recent Stories View Older Stories